targeting metastatic breast cancer with ang1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (bbb)
Clicks: 248
ID: 177384
2017
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
4.8
/100
16 views
16 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
We devoted this short interview piece with Dr Shou-Ching Tang at Augusta University to feature some promising results from a clinical phase II trial on a novel brain-penetrating peptide-paclitaxel-conjugate, ANG1005, in treating brain metastatic breast cancer. These results were presented by Dr. Tang at the recent annual meeting of the European Society for Medical Oncology (ESMO 2016 Congress). This development heralds an important step forward towards the development of effective chemotherapeutic agents, which can cross the blood-brain-barrier and effectively treat and prevent the brain metastatic cancers.
| Reference Key |
li2017genestargeting
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Fei Li |
| Journal | Journal of voice : official journal of the Voice Foundation |
| Year | 2017 |
| DOI |
10.1016/j.gendis.2017.01.004
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.